Object Details
maker
Genentech, Inc.
Description (Brief)
(From insert) KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:
--Received prior therapy for metastatic disease, or
-- Developed disease rescurrence during or within six months of completing adjuvant therapy.
Location
Currently not on view
Credit Line
Gift of Genentech, Inc.
date made
ca 2013
product expiration date
2015-11
ID Number
2013.0069.06
catalog number
2013.0069.06
accession number
2013.0069
Object Name
pharmaceutical
biological
Physical Description
plastic (overall material)
glass (overall material)
metal (overall material)
cardboard (overall material)
ado-trastuzumab emtansine, 160mg (overall ingredient)
Measurements
overall: 1 1/2 in x 2 3/4 in x 5 1/4 in; 3.81 cm x 6.985 cm x 13.335 cm
bottle of kadcyla: 2 1/2 in x 1 1/4 in; 6.35 cm x 3.175 cm
overall: 5 3/8 in x 2 3/4 in x 1 3/8 in; 13.6525 cm x 6.985 cm x 3.4925 cm
place made
United States: California, South San Francisco
See more items in
Medicine and Science: Medicine
Health & Medicine
The Antibody Initiative
Antibody Initiative: Monoclonal Antibodies
Data Source
National Museum of American History
Subject
Women's Health
Link to Original Record
Record ID
nmah_1445167